Prolonged converting enzyme inhibition following captopril in patients with renal insuffficiency.
作者信息
Campbell B C, Shepherd A N, Elliott H L, McLean K, Reid J L
出版信息
Br J Clin Pharmacol. 1982 May;13(5):755-7. doi: 10.1111/j.1365-2125.1982.tb01455.x.
Abstract
摘要
相似文献
1
Prolonged converting enzyme inhibition following captopril in patients with renal insuffficiency.肾功能不全患者在服用卡托普利后长期使用转换酶抑制剂。
Br J Clin Pharmacol. 1982 May;13(5):755-7. doi: 10.1111/j.1365-2125.1982.tb01455.x.
2
Captopril: an oral angiotension converting enzyme inhibitor active in man.卡托普利：一种对人体有效的口服血管紧张素转换酶抑制剂。
Arch Int Pharmacodyn Ther. 1980;Suppl:188-212.
3
Effect of converting enzyme inhibition on the systemic and renal responses to acute isotonic volume expansion in normal men.转换酶抑制对正常男性急性等渗容量扩张时全身及肾脏反应的影响。
Clin Sci (Lond). 1981 Dec;61 Suppl 7:285s-287s. doi: 10.1042/cs061285s.
4
Low temperature sustains inhibition of angiotensin-converting-enzyme activity in serum from patients taking captopril.低温维持服用卡托普利患者血清中血管紧张素转换酶活性的抑制状态。
N Engl J Med. 1981 Jul 23;305(4):229. doi: 10.1056/NEJM198107233050425.
5
6
The influence of ACE-inhibition by captopril on renal formation and metabolism of angiotensins I and II in patients with renovascular hypertension.
Scand J Urol Nephrol Suppl. 1984;79:45-8.
7
Inhibition of angiotensin-converting enzyme: therapeutic implications.
Isr J Med Sci. 1982 Oct;18(10):981-5.
8
9
[Effect of renal insufficiency on the pharmacokinetics of captopril and converting enzyme inhibition in the hypertensive patient].
Arch Mal Coeur Vaiss. 1984 Oct;77(11):1216-9.
引用本文的文献
1
Application of a physiologically based pharmacokinetic model in predicting captopril disposition in children with chronic kidney disease.应用生理药代动力学模型预测慢性肾脏病儿童卡托普利的处置。
Sci Rep. 2023 Feb 15;13(1):2697. doi: 10.1038/s41598-023-29798-0.
2
Inhibitors of the angiotensin I converting enzyme as antihypertensive drugs.作为抗高血压药物的血管紧张素I转换酶抑制剂。
Pharm Weekbl Sci. 1983 Oct 21;5(5):197-204. doi: 10.1007/BF02332943.
3
Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients.慢性肾衰竭对高血压患者卡托普利药代动力学及临床和生物学效应的影响。
Br J Clin Pharmacol. 1984 Nov;18(5):749-58. doi: 10.1111/j.1365-2125.1984.tb02538.x.
4
The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: comparison with patients with normal renal function.卡托普利及其二硫化物共轭物在维持性透析的尿毒症患者中的药代动力学：与肾功能正常患者的比较。
Eur J Clin Pharmacol. 1987;32(3):267-71. doi: 10.1007/BF00607574.
5
Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.年龄与血管紧张素转换酶抑制剂依那普利和依那普利拉的药代动力学
Br J Clin Pharmacol. 1986 Apr;21(4):341-8. doi: 10.1111/j.1365-2125.1986.tb05205.x.
本文引用的文献
1
Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure.慢性肾功能衰竭患者中卡托普利（SQ 14,225）的血药浓度及尿排泄情况。
Hypertension. 1981 Jul-Aug;3(4):456-9. doi: 10.1161/01.hyp.3.4.456.
2
Effects of the angiotensin converting enzyme inhibitor, captopril, in essential hypertension.血管紧张素转换酶抑制剂卡托普利对原发性高血压的作用。
Br J Clin Pharmacol. 1982 Feb;13(2):213-7. doi: 10.1111/j.1365-2125.1982.tb01359.x.
3
Opposite effects of captopril on angiotensin I-converting enzyme 'activity' and 'concentration'; relation between enzyme inhibition and long-term blood pressure response.卡托普利对血管紧张素I转换酶“活性”和“浓度”的相反作用；酶抑制与长期血压反应之间的关系。
Clin Sci (Lond). 1981 May;60(5):491-8. doi: 10.1042/cs0600491.
4
The measurement of angiotensin-converting enzyme in subjects receiving captopril.
N Engl J Med. 1980 Aug 14;303(7):397. doi: 10.1056/NEJM198008143030717.
5
A sensitive radioenzymatic assay for norepinephrine in tissues and plasma.一种用于检测组织和血浆中去甲肾上腺素的灵敏放射酶分析法。
Life Sci. 1975 Feb 1;16(3):375-84. doi: 10.1016/0024-3205(75)90258-1.
6
A liquid chromatography-assisted assay for angiotensin-converting enzyme (peptidyl dipeptidase) in serum.一种用于血清中血管紧张素转换酶（肽基二肽酶）的液相色谱辅助测定法。
Clin Chem. 1979 Jul;25(7):1259-62.
7
Captopril in the treatment of clinical hypertension and cardiac failure.
Lancet. 1979 Oct 20;2(8147):836-9. doi: 10.1016/s0140-6736(79)92186-x.
Zotero 插件